FindTrial
Sign In

BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL - ND

BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-013062-11-IT
Enrollment
Unknown
Registered
2009-06-16
Start date
2007-03-29
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age Related Macular Degeneration MedDRA version: 9.1 Level: LLT Classification code 10015902 Term: Exudative senile macular degeneration of retina

Interventions

Trade Name: AVASTIN Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bevacizumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-

Sponsors

AZIENDA USL 8 AREZZO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a) Patients > 50 years with active AMD b)Females had to be in menopause from a year Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: a)Poorly controlled Hypertension b)Evidence of bleeding or clotting problems c)Renal failure

Design outcomes

Primary

MeasureTime frame
Main Objective: Compare efficacy and safety of the three treatments;Secondary Objective: Number of injections made;Primary end point(s): Proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026